- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05860153
Intermittent Levetricetam in Treatment of Febrile Convulsions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The American Academy of Pediatrics (AAP) in 2011 published a clinical practice guideline defining a febrile seizure as "a seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method), without central nervous system infection, that occurs in infants and children 6 through 60 months of age." Febrile seizures are further classified as simple (generalized in onset, last less than 15 minutes, and do not occur more than once in 24 hours.) or complex (FS duration longer than 15 min, repeated convulsions within the same day, and focal seizure activity or focal findings during the postictal period.).
Epidemiology Approximately 8% of people will experience at least one seizure episode during their lifetime. Up to 30% of such episodes are febrile seizures (FS), which are the most commonly occurring seizures in 2 to 5% of all children. Nevertheless, although FS is a benign condition in most cases and the prognosis is good generally and recurrences do not impair the prognosis in children who were neurologically normal before their first febrile seizure, FS episodes constitute a traumatic experience, it is a very frightening event for the parents/caregivers witnessing a tonic-clonic seizure, especially for the patients with frequent FS, they suffer extreme anxiety for recurrences of seizures or development of epilepsy; FS is also likely one of the most frequent causes of admittance to pediatric emergency ward worldwide. In any case, febrile seizures should be taken under serious consideration.
During seventies ten eligible clinical trials were included. Prophylaxis with either phenobarbital or diazepam reduces recurrences of febrile seizures.
After oral administration >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 - 1.5 hours with a range of 0.25 to 2.5 hours. The mean half-life of diazepam has been reported to be 18 hours. Intermittent diazepam in oral or anal form is effective In preventing the recurrence of febrile seizures as diazepam however, the side effects associated with intermittent diazepam in the prevention of febrile seizures outweight it's potential benefits including sedation, behavioral changes, gastrointestinal and hematologic toxicity, hypersensitivity reactions, and rare fatal hepatotoxicity with VPA in young children. And also the intermittent administration of benzodiazepines (e.g., diazepam and midazolam) at the onset of fever is effective, but the effectiveness of this treatment is limited because sedative effects can mask the signs and symptoms of any evolving central nervous system infections.
After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is ≥95%. LEV was reported to induce psychotropic side effects in up to 30% of patients. These adverse effects include beneficial effects such as enhancement of drive and cognition on the one hand and behavioral disturbances such as irritability, aggression, agitation, anger, anxiety, apathy, and hostility on the other hand.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kariman Hussein
- Phone Number: 01014121203
- Email: karimanhussein219@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Included children 6 months to 36 months with febrile seizures after exclusion of CNS infections .
Exclusion Criteria:
- Non-febrile seizures
- Head trauma
- CNS infections
- Known metabolic diseases
- Known genetic disorders
- Developmental delay
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group (A)
• Group (A) will receive oral levetiracetam at a dose of 15-20 mg/kg/day twice daily at the onset of fever (temperature >37.5 c) for 48h after subsiding of fever.
|
Group with oral levetiracetam at a dose of 15-20 mg/kg/day
Other Names:
|
Experimental: Group (B)
• Group (B) will receive diazepam at a dose of 0.3 mg/kg/dose was given every eight hours for 48h after subsiding of fever Children were followed up for 12 months to find out seizure frequency associated with febrile events and febrile seizure recurrence rate during 12 months follow-up
|
Group with diazepam at a dose of 0.3 mg/kg/dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of therapeutic effect of oral levetiracetam on febrile convulsions
Time Frame: Baseline
|
The rate of therapeutic effect of oral levetiracetam in reducing the recurrence of febrile seizures in children aged 6-36months.
|
Baseline
|
The rate of therapeutic effect of intermittent diazepam on febrile convulsions
Time Frame: Baseline
|
The rate of therapeutic effect of intermittent diazepam in reducing the recurrence of febrile seizures in children aged 6-36months.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Khaled Elsayah, Prof, Assiut University
- Principal Investigator: Khalaf Abd El-Aal, Assist prof, Assiut University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Body Temperature Changes
- Heat Stress Disorders
- Seizures
- Hyperthermia
- Fever
- Seizures, Febrile
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Neuromuscular Agents
- Nootropic Agents
- Muscle Relaxants, Central
- Diazepam
- Levetiracetam
Other Study ID Numbers
- Febrile convulsions treatment
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Febrile Convulsion
-
University Hospital, ToulouseNot yet recruiting
-
Queen Sirikit National Institute of Child HealthRecruitingRecurrent Febrile ConvulsionThailand
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaUnknownGastroenteritis | Bronchiolitis | Convulsion, FebrileSlovenia
-
Assiut UniversityNot yet recruitingNeonatal Convulsion
-
Institut za Rehabilitaciju Sokobanjska BeogradCompletedFebrile SeizureSerbia
-
Denver Health and Hospital AuthorityCompletedConvulsion, Non-EpilepticUnited States
-
Institut za Rehabilitaciju Sokobanjska BeogradCompleted
-
Sohag UniversityCompleted
-
Centre Hospitalier Universitaire DijonCompletedInfants Likely to Present Febrile ConvulsionsFrance
-
University of Alabama at BirminghamActive, not recruitingConvulsion, Non-EpilepticUnited States
Clinical Trials on Levetiracetam
-
Johns Hopkins UniversityNational Institute on Aging (NIA)CompletedMild Cognitive Impairment (MCI)United States
-
UCB Pharma SACompleted
-
Odense University HospitalCompleted
-
Richard H. HaasThrasher Research FundCompletedSeizures | Disorder of Fetus or NewbornUnited States
-
UCB Japan Co. Ltd.CompletedEpilepsies, PartialJapan
-
Odense University HospitalCompleted
-
Oslo University HospitalUnknownSubclinical Sleep-Activated Epileptiform Activity | CSWSNorway
-
National Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
Odense University HospitalCompleted
-
UCB PharmaParexelCompletedHealthy Subjects | Renal ImpairmentsJapan